Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by BVF Inc. IL

BVF Inc. IL decreased its position in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 23.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,567,469 shares of the company's stock after selling 804,292 shares during the period. Kura Oncology accounts for about 0.8% of BVF Inc. IL's investment portfolio, making the stock its 27th biggest position. BVF Inc. IL owned approximately 3.30% of Kura Oncology worth $22,363,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its holdings in shares of Kura Oncology by 969.9% in the 4th quarter. BNP Paribas Financial Markets now owns 163,559 shares of the company's stock worth $1,425,000 after buying an additional 148,272 shares during the period. Ameriprise Financial Inc. purchased a new stake in Kura Oncology in the fourth quarter worth about $130,000. Alethea Capital Management LLC lifted its stake in Kura Oncology by 0.9% in the fourth quarter. Alethea Capital Management LLC now owns 558,442 shares of the company's stock worth $4,864,000 after acquiring an additional 4,900 shares during the period. Algert Global LLC grew its holdings in Kura Oncology by 224.6% during the 4th quarter. Algert Global LLC now owns 883,703 shares of the company's stock worth $7,697,000 after acquiring an additional 611,427 shares in the last quarter. Finally, RA Capital Management L.P. purchased a new position in Kura Oncology during the 4th quarter valued at about $38,769,000.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on KURA. Wedbush reiterated an "outperform" rating and set a $36.00 price objective on shares of Kura Oncology in a research note on Tuesday, April 8th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Kura Oncology in a research report on Monday, April 28th. Scotiabank reduced their price target on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 8th. Cantor Fitzgerald raised Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. Finally, Barclays reduced their target price on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $23.89.

Kura Oncology Stock Performance

NASDAQ:KURA traded down $0.15 during trading hours on Wednesday, hitting $5.64. 1,437,984 shares of the company were exchanged, compared to its average volume of 1,167,658. The company's 50 day moving average price is $6.63 and its 200-day moving average price is $9.39. The stock has a market capitalization of $455.59 million, a price-to-earnings ratio of -2.39 and a beta of 0.50. Kura Oncology, Inc. has a 52-week low of $5.41 and a 52-week high of $23.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million. As a group, research analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.